期刊文献+

天然抗ABCC3 IgG抗体对口腔鳞癌细胞增殖的影响 被引量:6

Effect of natural anti-ABCC3 antibodies on oral squamous cell carcinoma
下载PDF
导出
摘要 目的探讨天然抗ABCC3 IgG抗体对口腔鳞癌细胞CAL27和SCC15的影响。方法采用ELISA方法筛查富含天然抗ABCC3 IgG抗体的阳性血浆为实验组,低含天然抗ABCC3 IgG抗体的阴性血浆为对照组。采用qRT-PCR检测ABCC3基因的mRNA表达水平。CCK-8实验和流式细胞术检测天然抗ABCC3 IgG抗体对CAL27和SCC15细胞的增殖、凋亡和细胞周期的影响。结果在CAL27和SCC15细胞中均有ABCC3基因的表达。与阴性对照血浆相比较,富含ABCC3 IgG抗体的阳性血浆可以明显抑制CAL27细胞的增殖(P<0.01),促进CAL27细胞的凋亡(P<0.01),并对CAL27细胞周期中的G2/M期产生阻滞作用(P<0.01),但对SCC15细胞无明显影响。结论天然抗ABCC3 IgG抗体对口腔鳞癌细胞的增殖有抑制作用,可能成为治疗口腔鳞癌的一种有前景的新药物。 Objective To investigate the effect of natural anti-ABCC3 antibodies on oral squamous cell carcinoma (OSCC) cell lines, CAL27 and SCC15. Methods An in-house enzyme-linked immune-sorbent assay (ELISA) was performed to detect the anti-ABCC3 IgG antibodies in human plasma and then CAL27 and SCC15 cells were treated with plasmas. Plasma with low anti-ABCC3 IgG antibodies was used as control and ABCC3 expression was identified by quantitative RT-PCR. CCK-8 assay and flow cytometry was used to evaluate the effect of anti-ABCC3 IgG antibodies on proliferation, apoptosis and cell cycle of cells. Results The plasma rich in natural anti-ABCC3 IgG antibodies significantly inhibited the proliferation of CAL27 cells ( P <0.01), but had no remarkable suppressive effect on SCC15 cells though the expression of ABCC3 gene was found in both CAL27 and SCC15 cells. It could also reduce the apoptosis of CAL27 cells ( P <0.01) and arrest the G2/M phase of CAL27 cell cycle ( P <0.01). Conclusion The natural anti-ABCC3 IgG antibodies may be a potential therapy for the treatment of OSCC.
作者 刘秀 黄志成 董蕊 何子毅 孟庆勇 胡颖 LIU Xiu;HUANG Zhi-cheng;DONG Rui;HE Zi-yi;MENG Qing-yong;HU Ying(Beijing Institute of Dental Research, Capital Medical University School of Stomatology, Beijing 100050, China)
出处 《北京口腔医学》 CAS 2019年第2期67-71,共5页 Beijing Journal of Stomatology
基金 国家自然科学基金(81570958) 北京市自然科学基金(7162075)
关键词 天然抗体 ABCC3 口腔鳞癌 Natural antibody ABCC3 Oral squamous cell carcinoma
  • 相关文献

参考文献3

二级参考文献28

  • 1王洁,刘叙仪,蒋薇.Co-transfection of MRP and bcl-2 antisense S-oligodeoxynucleotides reduces drug resistance in cisplatin-resistant lung cancer cells[J].Chinese Medical Journal,2000(10):93-96. 被引量:16
  • 2王彦,吴焕明.肺癌中金属硫蛋白的表达及其与细胞增殖、凋亡的关系[J].中国组织化学与细胞化学杂志,2003,12(4):393-398. 被引量:7
  • 3Yan Xin,Denise Jin,Stephen Eppler,Lisa A. Damico-Beyer,Amita Joshi,John D. Davis,Surinder Kaur,Ihsan Nijem,John Bothos,Amy Peterson,Premal Patel,Shuang Bai.Population Pharmacokinetic Analysis From Phase I and Phase II Studies of The Humanized Monovalent Antibody, Onartuzumab (MetMAb), in Patients With Advanced Solid Tumors[J].Journal of Clinical Pharmacology.2013(11)
  • 4Hagop Kantarjian,Deborah Thomas,Jeffrey Jorgensen,Partow Kebriaei,Elias Jabbour,Michael Rytting,Sergernne York,Farhad Ravandi,Rebecca Garris,Monica Kwari,Stefan Faderl,Jorge Cortes,Richard Champlin,Susan O’Brien.Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia[J].Cancer.2013(15)
  • 5Deborah K. Armstrong,Allen J. White,Susan C. Weil,Martin Phillips,Robert L. Coleman.Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer[J].Gynecologic Oncology.2013(3)
  • 6Michinori Ogura,Kensei Tobinai,Kiyohiko Hatake,Toshiki Uchida,Tatsuya Suzuki,Yukio Kobayashi,Masakazu Mori,Yasuhito Terui,Masahiro Yokoyama,Tomomitsu Hotta.Phase I study of obinutuzumab ( GA 101) in J apanese patients with relapsed or refractory B ‐cell non‐ H odgkin lymphoma[J].Cancer Sci.2012(1)
  • 7Anas Younes,Ajay K. Gopal,Scott E. Smith,Stephen M. Ansell,Joseph D. Rosenblatt,Kerry J. Savage,Radhakrishnan Ramchandren,Nancy L. Bartlett,Bruce D. Cheson,Sven de Vos,Andres Forero-Torres,Craig H. Moskowitz,Joseph M. Connors,Andreas Engert,Emily K. Larsen,Dana A. Kennedy,Eric L. Sievers,Robert Chen.Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin’s Lymphoma[J].Journal of Clinical Oncology.2012(18)
  • 8Barbara Pro,Ranjana Advani,Pauline Brice,Nancy L. Bartlett,Joseph D. Rosenblatt,Tim Illidge,Jeffrey Matous,Radhakrishnan Ramchandren,Michelle Fanale,Joseph M. Connors,Yin Yang,Eric L. Sievers,Dana A. Kennedy,Andrei Shustov.Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study[J].Journal of Clinical Oncology.2012(18)
  • 9Sandhya Girish,Manish Gupta,Bei Wang,Dan Lu,Ian Krop,Charles Vogel,Howard Burris III,Patricia LoRusso,Joo-Hee Yi,Ola Saad,Barbara Tong,Yu-Waye Chu,Scott Holden,Amita Joshi.Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer[J].Cancer Chemotherapy and Pharmacology.2012(5)
  • 10N.N. Shah,D. Bhojwani,L.B. Silverman,J.A. Whitlock,K. Richards,M. Stetler-Stevenson,M. Buzoianu,R. Ibrahim,I. Pastan,A.S. Wayne.A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox (HA22, CAT-8015): Activity in Pediatric Patients with Relapsed Acute Lymphoblastic Leukemia (ALL) After Allogeneic Hematopoietic Stem Cell Transplantation (SCT)[J].Biology of Blood and Marrow Transplantation.2012(2)

共引文献17

同被引文献12

引证文献6

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部